60023-35-0

Usage

Uses

Used in Organic Synthesis:
Pyrazine, (bromomethyl)(9CI) is used as a building block in organic synthesis for the production of various fine chemicals and medicinal compounds. Its unique molecular structure and reactivity contribute to the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Pyrazine, (bromomethyl)(9CI) is used as an intermediate in the synthesis of pharmaceutical compounds. Its versatile chemical properties allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemicals:
Pyrazine, (bromomethyl)(9CI) is also utilized in the agrochemical industry for the development of pesticides and other agricultural chemicals. Its chemical properties make it suitable for the creation of effective and targeted agrochemical products.

InChI:InChI=1/C5H5BrN2/c6-3-5-4-7-1-2-8-5/h1-2,4H,3H2

Upstream product

• 109-08-0 2-Methylpyrazine 
• 6164-79-0 methyl pyrazine-2-carboxylate 
• 6705-33-5 pyrazin-2-ylmethanol 

Downstream Products

• 950889-30-2 (2R,3R)-3-Hydroxy-3-methyl-1-[4-(pyrazin-2-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Nonameric porphyrin assemblies - Formation and intra-assembly energy transfer reactions

The nonameric porphyrin assemblies constructed with the series of free base tetraphenylporphyrins Pn having four pyrazine moieties linked with alkyl chains of different lengths, (CH2)n (n- 1, 5, 9, 17, 30), and dimeric [mesotetrakis(2-carboxy-4-nonylphenyl)porphyrinato]zinc(II), ZnP2, show the effective light-collection effect and the typical Foerster-type energy transfer from ZnP2 to Pn.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide???Heteroarene π-Stacking Interactions and Chalcogen Bonding in the S3 Pocket

We report an extensive “heteroarene scan” of triazine nitrile ligands of the cysteine protease human cathepsin L (hCatL) to investigate π-stacking on the peptide amide bond Gly67–Gly68 at the entrance of the S3 pocket. This heteroarene???peptide bond stacking was supported by a co-crystal structure of an imidazopyridine ligand with hCatL. Inhibitory constants (Ki) are strongly influenced by the diverse nature of the heterocycles and specific interactions with the local environment of the S3 pocket. Binding affinities vary by three orders of magnitude. All heteroaromatic ligands feature enhanced binding by comparison with hydrocarbon analogues. Predicted energetic contributions from the orientation of the local dipole moments of heteroarene and peptide bond could not be confirmed. Binding of benzothienyl (Ki=4 nm) and benzothiazolyl (Ki=17 nm) ligands was enhanced by intermolecular C?S???O=C interactions (chalcogen bonding) with the backbone C=O of Asn66 in the S3 pocket. The ligands were also tested for the related enzyme rhodesain.

Substituted bis-amide metalloprotease inhibitors

This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, wherein P Q X1 X2 X3 X4 X5 R R1 R2 R3 R4R5 G M1 M2 M3 m and n are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.